​

Viking Therapeutics (VKTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

VKTX Stock Forecast

Viking Therapeutics (VKTX) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $103.00, with a high of $107.00 and a low of $99.00. This represents a 190.39% increase from the last price of $35.47.

$15 $34 $53 $72 $91 $110 High: $107 Avg: $103 Low: $99 Last Closed Price: $35.47

VKTX Stock Rating

Viking Therapeutics stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 1 Strong Buy (4.35%), 21 Buy (91.30%), 1 Hold (4.35%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 1 21 1 Strong Sell Sell Hold Buy Strong Buy

VKTX Price Target Upside V Benchmarks

TypeNameUpside
StockViking Therapeutics190.39%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts127
Avg Price Target$101.00$100.00$99.29
Last Closing Price$35.47$35.47$35.47
Upside/Downside184.75%181.93%179.93%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 265121--18
Feb, 265121--18
Jan, 265121--18
Dec, 255121--18
Nov, 256111--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 12, 2026Roger SongJefferies$101.00$35.47184.75%184.75%
Feb 12, 2026Michael UlzMorgan Stanley$99.00$31.07218.64%179.11%
Nov 12, 2025Edward NashCanaccord Genuity$107.00$40.60163.55%201.66%
Oct 29, 2025Edward NashCanaccord Genuity$106.00$34.93203.46%198.84%
Oct 23, 2025Morgan Stanley$102.00$31.42224.63%187.57%
Oct 23, 2025Cantor Fitzgerald$105.00$31.42234.18%196.02%
Apr 28, 2025Joon LeeTruist Financial$75.00$25.94189.13%111.45%
Dec 02, 2024Biren AminPiper Sandler$74.00$52.9439.78%108.63%
Nov 04, 2024Yale JenLaidlaw$110.00$63.1474.22%210.12%
Nov 04, 2024Roger SongJefferies$110.00$63.1474.22%210.12%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 12, 2026JefferiesBuyBuyhold
Feb 12, 2026Morgan StanleyOverweightOverweighthold
Dec 18, 2025H.C. WainwrightPositivePositivehold
Nov 12, 2025Canaccord GenuityBuyBuyhold
Oct 29, 2025Canaccord GenuityBuyinitialise
Oct 23, 2025Morgan StanleyOverweightOverweighthold
Sep 22, 2025BTIGBuyBuyhold
Jun 25, 2025BTIGBuyBuyhold
Apr 28, 2025Cantor FitzgeraldOverweightinitialise
Apr 14, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.91$-1.01$-3.19---
Avg Forecast$-0.92$-0.95$-1.49$-1.83$-1.80$-0.34
High Forecast$-0.88$-0.78$-1.21$-0.32$2.05$-0.34
Low Forecast$-0.94$-1.28$-2.19$-2.74$-3.74$-0.34
Surprise %-1.09%6.32%114.09%---

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast--$2.50M$35.54M$124.95M$430.93M
High Forecast--$2.50M$35.54M$124.95M$430.93M
Low Forecast--$2.50M$35.54M$124.95M$430.93M
Surprise %------

Net Income Forecast

$-400M $-280M $-160M $-40M $80M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-85.89M$-109.96M$-359.64M---
Avg Forecast$-85.89M$-99.15M$-167.28M$-209.46M$-224.26M$-32.35M
High Forecast$-83.39M$-73.18M$-114.61M$-30.59M$193.69M$-32.35M
Low Forecast$-89.01M$-120.42M$-206.30M$-258.13M$-353.26M$-32.35M
Surprise %-10.90%115.00%---

VKTX Forecast FAQ

Is Viking Therapeutics stock a buy?

Viking Therapeutics stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 21 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Viking Therapeutics is a favorable investment for most analysts.

What is Viking Therapeutics's price target?

Viking Therapeutics's price target, set by 23 Wall Street analysts, averages $103 over the next 12 months. The price target range spans from $99 at the low end to $107 at the high end, suggesting a potential 190.39% change from the previous closing price of $35.47.

How does Viking Therapeutics stock forecast compare to its benchmarks?

Viking Therapeutics's stock forecast shows a 190.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Viking Therapeutics over the past three months?

  • March 2026: 27.78% Strong Buy, 66.67% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 27.78% Strong Buy, 66.67% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 27.78% Strong Buy, 66.67% Buy, 5.56% Hold, 0% Sell, 0% Strong Sell.

What is Viking Therapeutics’s EPS forecast?

Viking Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.83, marking a -42.63% decrease from the reported $-3.19 in 2025. Estimates for the following years are $-1.8 in 2027, and $-0.34 in 2028.

What is Viking Therapeutics’s revenue forecast?

Viking Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $35.54M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $124.95M, and $430.93M for 2028.

What is Viking Therapeutics’s net income forecast?

Viking Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-209M, representing a -41.76% decrease from the reported $-360M in 2025. Projections indicate $-224M in 2027, and $-32.348M in 2028.